NCT01323985View on ClinicalTrials.gov

SAP Depleter Dose Escalation Study in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

January 6, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

Amyloidosis

Interventions

DRUG

GSK2315698

5mg-400mg IV (in the vein) single dose over 1-4 hours

DRUG

GSK2315698

IV (in the vein) single dose over 24 hours, in two sessions

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01323985 - SAP Depleter Dose Escalation Study in Healthy Volunteers | Biotech Hunter | Biotech Hunter